Skip to main content
. Author manuscript; available in PMC: 2015 Mar 15.
Published in final edited form as: Cancer Res. 2014 Jan 28;74(6):1651–1660. doi: 10.1158/0008-5472.CAN-13-3159

Figure 3.

Figure 3

PCAT-1 expression results in prostate cell sensitivity to PARP inhibition in vitro and in vivo. A, Left, LNCaP cells with PCAT-1 knockdown exhibit enhanced cell survival 72 hrs post-treatment with Olaparib. Right, Du145 cells with PCAT-1 overexpression exhibit reduced cell survival 72 hrs post-treatment with Olaparib. Cell survival is determined via WST assays. B, BRCA2 knockdown in LNCaP shPCAT-1 cells rescues cell sensitivity to Olaparib. An inset Western blot showing efficiency of BRCA2 knockdown is included. C, Tumor growth curves for Du145-control and Du145-PCAT-1 xenografts following initiation of treatment with DMSO control or 25uM Olaparib. Tumor volumes are normalized to 100, and time = 0 represents the start of treatment administration. Treatment was initiated three weeks after xenograft engraftment. D, Expression level of PCAT-1and BRCA2 protein in Du145-PCAT-1 xenografts. Error bars in this figure represent +/− S.E.M.